|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Alexza Pharmaceuticals, Inc.
| | | Phone: | (650) 944-7000 | Fax: | (650) 944-7999 | Year Established: | 2000 | Employees: | 100 | Ticker: | ALXA | Exchange: | NASDAQ | Main Contact: | Tatjana Naranda, Ph.D., President & COO | | Other Contacts: | Stacy Palermini, VP, Finance and Corporate Secretary & Treasurer Catherine McAuliffe, VP, Operations Edwin S. Kamemoto, Ph.D, Executive VP, R&D, Regulatory & Quality
| | Company Description | Alexza Pharmaceuticals is focused on the research, development, and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions. Alexza's products and development pipeline are based on the Staccato® system, a hand-held inhaler designed to deliver a pure drug aerosol to the deep lung, providing rapid systemic delivery and therapeutic onset, in a simple, non-invasive manner. Active pipeline product candidates include AZ-002 (Staccato alprazolam) for the management of epilepsy in patients with acute repetitive seizures and AZ-007 (Staccato zaleplon) for the treatment of patients with middle of the night insomnia. | |
|
|
|
|
|